Some main licensed hashish producers in Colombia raised contemporary rounds of capital just lately.
Khiron Life Sciences – a Toronto-based firm with its predominant operations in Colombia – closed a purchased deal for 14.5 million Canadian {dollars} ($11.5 million), it disclosed on Nov. 26.
Pharmacielo, additionally headquartered in Toronto and working primarily in Colombia, closed a personal placement for proceeds of CA$10 million earlier this week.
Each corporations stated they plan to make use of the added capital for normal company functions.
Pharmacielo was all the way down to C$5.1 million in money and equivalents as of June 30 – its newest disclosed monetary quarter.
The corporate recorded a lack of CA$7.7 million tor the three-month interval.
In a company replace earlier this month, Khiron stated it had CA$14.7 million in money and equivalents as of the tip of September.
The corporate stated it crammed more than 4,600 medical hashish prescriptions in Colombia as of Oct. 31, and expects to see “regular, quarter on quarter income progress” when it stories its July-September quarter.
Nevertheless, in a brief type prospectus filed this week, Khiron tempered expectations.
“Because of the impression of COVID-19, in addition to delays in regulatory developments in sure markets, similar to Uruguay, Brazil and Mexico, the corporate’s progress expectations have been tempered,” it stated within the regulatory submitting.
Khiron recorded a web lack of CA$5.7 million within the quarter ended June 30.
Pharmacielo’s enterprise is extra targeted on exporting from Colombia.
However up to now exports from Colombia totaled solely $4.1 million as of August.
Shares of Khiron and Pharmacielo commerce on the TSX Enterprise Alternate as KHRN, and PCLO, respectively.
